Bayer's New Prostate Cancer Drug Beats Sales Expectations
January 13 2021 - 5:09AM
Dow Jones News
By Olaf Ridder
Bayer AG said Wednesday that its new prostate cancer drug,
Nubeqa, has outperformed sales expectations.
The German chemicals company did not disclose exact sales
figures in an interview with the Wall Street Journal, but its head
of pharmaceuticals Stefan Oelrich said the drug has exceeded all
expectations and sold well in the U.S. and Europe.
"We have a product which is unmatched in its effects and side
effects profiles, and that is something we hear back from doctors
too," Mr. Oelrich said.
Bayer expects annual sales of the new drug to be worth over one
billion euros ($1.22 billion).
Write to Olaf Ridder at olaf.ridder@wsj.com
(END) Dow Jones Newswires
January 13, 2021 04:54 ET (09:54 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Bayer (TG:BAYN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bayer (TG:BAYN)
Historical Stock Chart
From Sep 2023 to Sep 2024